TITLE

beyond NEEDLES and PILLS

AUTHOR(S)
Jaroff, Leon; Bjerklie, David
PUB. DATE
January 2001
SOURCE
Time International (South Pacific Edition);1/15/2001, Issue 2, p70
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the development of devices to administer medicine to patients. Discussion of the costs and amount of death due to harmful reactions to drugs; How natural body defenses, such as the blood-brain barrier and the macrophages of the immune system, block administered drugs; Description of a device called the Mosquito, which is a small disk equipped with a tiny needle; Discussion of transdermal patches; Difficulty of administering the correct dosage of medicine to a patient.
ACCESSION #
3980142

 

Related Articles

  • beyond NEEDLES and PILLS. Jaroff, Leon; Bjerklie, David // Time;1/15/2001, Vol. 157 Issue 2, p94 

    Reports on the development of devices to administer medicine to patients. Discussion of the costs and amount of death due to harmful reactions to drugs; How natural body defenses, such as the blood-brain barrier and the macrophages of the immune system, block administered drugs; Description of...

  • Where to report serious adverse drug reactions.  // Consumer Reports on Health;Jul2001, Vol. 13 Issue 7, p10 

    States that patients should report serious reactions or injuries caused by a drug or medical device to the MedWatch program of the United States Food and Drug Administration (FDA). Adverse-drug reaction reports received by the FDA in 2000; Call for consumers to encourage their doctors to report...

  • Rivastigmine transdermal patch: a guide to its use in dementia of the Alzheimer's type.  // Drugs & Therapy Perspectives;Apr2008, Vol. 24 Issue 4, p5 

    The article presents a guide to the use of rivastigmine transdermal patch in dementia of the Alzheimer's type. A summary of the dosage and administration of rivastigmine patch in the treatment of patients with Alzheimer's disease is provided. The efficacy of the formulation, its adverse effects,...

  • Rivastigmine Transdermal Patch: In the Treatment of Dementia of the Alzheimer's Type. Yang, Lily P .H.; Keating, Gillian M. // CNS Drugs;2007, Vol. 21 Issue 11, p957 

    The cholinesterase inhibitor rivastigmine is now available as a transdermal patch for use in the treatment of mild to moderate dementia of the Alzheimer's type. The transdermal patch gradually releases rivastigmine over the application period. There was less fluctuation between plasma peak and...

  • TRANSFEROSOME: LATEST UPDATES. Dilip Kumar, V.; Saraswathi, B.; Prudvi Kanth, N. // International Journal of Pharmaceutical Sciences & Research;Nov2013, Vol. 4 Issue 11, p4125 

    Poor patient compliance is a frequent problem in daily clinical practice. The unfavorable pharmacokinetic of the drug, the inconveniences of the standard form of such drug application and the side effects due to the administration route often are the reasons for this. The high and...

  • Second alert from US FDA for fentanyl skin patches.  // Reactions Weekly;1/12/2008, Issue 1184, p2 

    The article reports on a second safety warning issued by the U.S. Food & Drug Administration (FDA) regarding fentanyl transdermal patches. The safety warnings was prompted by continuing reports of death and life-threatening adverse events after either inappropriate prescribing or incorrect use...

  • WARNING Drug Alert.  // Pharmacy Today;Mar2004, Vol. 10 Issue 3, p3 

    Alerts consumers about the ill effects of certain drugs. Notification by the United States Food and Drug Administration (FDA) and Boehringer Ingel-heim of life-threatening or fatal hepatotoxicity in patients after treatment with nevirapine; Warning by the FDA and Johnson & Johnson on the sale...

  • No-Pill Bladder Control. Dellapena, Deb; Harrar, Sari // Prevention;Aug2003, Vol. 55 Issue 8, p164 

    Features the U.S. Food and Drug Administration-approved Oxytrol transdermal patch which controls symptoms of overactive bladder (OAB) for several days without pills. Side effects of the patch; Signs that a person had OAB.

  • Buprenorphine Transdermal Patch.  // AHFS Consumer Medication Information;Aug2020, p1 

    Buprenorphine skin patches are used to treat moderate to severe pain that is expected to last for some time. It is in a class of medications called opiate (narcotic) analgesics. It works by changing the way the brain and nervous system respond to pain.

Share

Read the Article

Other Topics